Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Merck announces collaboration with Advaxis

Authored by James Sheppard

The global pharmaceutical giant Merck & Co announced it had partnered with the New Jersey based biotech company Advaxis. The collaboration will see the pair test experimental immuno-oncology drug in combination with a high-profile immunotherapy drug from Merck for a treatment for advanced prostate cancer.

The deal will see Merck use evaluate the use of Advaxis’s ADXS-PSA as a stand-alone treatment and in combination with Merck’s PD-1 inhibitor, pembrolizumab, in a phase I/II clinical study. By using the two different approaches the companies hope the two drugs have a better chance of knocking down prostate cancer than either would achieve on its own.

Daniel O’Connor, CEO of Advaxis said ‘If the combination of drugs shows an added effect, the companies would likely continue their collaboration.’ David Mauro, Executive Director of Oncology at Merck added, ‘PD-1 inhibitors and other immuno-oncology drugs have already shown promise against other types of cancer, including melanoma, but have not yet been tested to any great extent against prostate cancer.’

The deal is the latest success for Advaxis who earlier in the year signed a deal with MedImmune (the biologics arm of AstraZeneca). This combined with some strong clinical data and orphan drug designations mean the small biotech is in a strong place to continue its push forward.

 

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap